Zhejiang Tianyu Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Zhejiang Tianyu Pharmaceutical's earnings have been declining at an average annual rate of -44.7%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 5.5% per year.
Key information
-44.7%
Earnings growth rate
-45.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 5.5% |
| Return on equity | -0.9% |
| Net Margin | -1.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Zhejiang Tianyu Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,440 | -32 | 430 | 241 |
| 31 Dec 23 | 2,527 | 27 | 428 | 244 |
| 30 Sep 23 | 2,447 | -89 | 394 | 246 |
| 31 Mar 23 | 2,694 | -103 | 411 | 233 |
| 31 Dec 22 | 2,667 | -119 | 420 | 231 |
| 30 Sep 22 | 2,690 | 37 | 420 | 231 |
| 30 Jun 22 | 2,652 | 119 | 440 | 223 |
| 31 Mar 22 | 2,536 | 156 | 469 | 231 |
| 01 Jan 22 | 2,545 | 205 | 470 | 227 |
| 30 Sep 21 | 2,523 | 295 | 449 | 223 |
| 30 Jun 21 | 2,623 | 466 | 427 | 224 |
| 31 Mar 21 | 2,778 | 634 | 399 | 202 |
| 31 Dec 20 | 2,587 | 667 | 366 | 179 |
| 30 Sep 20 | 2,532 | 719 | 353 | 153 |
| 30 Jun 20 | 2,464 | 713 | 345 | 129 |
| 31 Mar 20 | 2,181 | 624 | 330 | 114 |
| 31 Dec 19 | 2,111 | 586 | 323 | 112 |
| 30 Sep 19 | 2,046 | 529 | 327 | 103 |
| 30 Jun 19 | 1,799 | 377 | 299 | 93 |
| 31 Mar 19 | 1,666 | 271 | 290 | 86 |
| 31 Dec 18 | 1,467 | 164 | 270 | 79 |
| 30 Sep 18 | 1,309 | 73 | 235 | 74 |
| 30 Jun 18 | 1,226 | 65 | 189 | 95 |
| 31 Mar 18 | 1,201 | 89 | 195 | 76 |
| 31 Dec 17 | 1,188 | 100 | 205 | 59 |
| 30 Sep 17 | 1,149 | 128 | 214 | 40 |
| 31 Mar 17 | 1,055 | 109 | 242 | 0 |
| 31 Dec 16 | 1,082 | 122 | 232 | 0 |
| 31 Dec 15 | 840 | 50 | 192 | 0 |
| 31 Dec 14 | 777 | 24 | 156 | 0 |
| 31 Dec 13 | 723 | 34 | 145 | 0 |
Quality Earnings: 300702 is currently unprofitable.
Growing Profit Margin: 300702 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300702 is unprofitable, and losses have increased over the past 5 years at a rate of 44.7% per year.
Accelerating Growth: Unable to compare 300702's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300702 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 300702 has a negative Return on Equity (-0.92%), as it is currently unprofitable.